Using an approach similar to that successful in Huntington’s disease, researchers at University College London, UK, have obtained risk scores for motor progression, cognitive progression, and composite (motor and cognitive) progression in patients with Parkinson’s disease (PD).
To do so they applied case-control, genome‐wide association studies (GWASs) to systematically collected clinical data from more than 3,000 PD patients in three large, longitudinal, prospective cohorts followed up for a mean of 4.2 years.